BioCentury | Mar 13, 2018
Distillery Techniques

Disease models

...TECHNOLOGY: Transgenics and knockouts BAP1-knockout, transgenic mice with melanocyte-specific expression of mutant human GNA11 could be...
...human GNA11 could be used to screen therapies for metastatic uveal melanoma. Mice with systemic BAP1...
...steps could include using the model to screen metastatic uveal melanoma therapies. DESCRIPTION: Mice with BRCA1-associated protein 1 (BAP1)...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Pathways emerging from ASH

...“Epiphenomena at ASH.” BioCentury Innovations (Dec. 7, 2017)). In protein degradation , the ubiquitin ligases BAP1...
...indications. Companies and Institutions Mentioned American Society of Hematology (ASH), Washington, D.C. Targets BAP1 - BRCA1-associated protein 1...
...CRISPR/Cas9 enhances tumour rejection.” Nature (2017) Lauren Martz, Senior Writer American Society of Hematology 8-oxoguanine DNA glycosylase (OGG1) (HMMH) BRCA1-associated protein 1 (BAP1) Bromodomain...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...in ASH2017. Source: ASH abstracts as of Dec. 5, 2017 Target 2017 Abstracts 2016 Abstracts BRCA1-associated protein 1 (BAP1)...
...for ovarian cancer. A presentation from a Japanese team suggests inhibition of the deubiquitinating enzyme BAP1...
...ARID5B - AT-rich interaction domain 5B ASXL1 - Additional sex combs like 1 BAP1 - BRCA1-associated protein 1...
BioCentury | Nov 17, 2016
Product R&D

Hemorrhaging targets

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new...
BioCentury | Aug 15, 2016
Clinical News

Tazemetostat: Phase II started

...regardless of BRCA1-associated protein 1 (BAP1) status. The second part will enroll 55 patients with mesothelioma characterized by BAP1...
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: BRCA1-associated protein 1 (BAP1); enhancer of zeste homolog 2 (EZH2)

...mouse studies suggest inhibiting EZH2 could help treat BAP1-mutant cancers and myeloproliferative disorder. In human BAP1-mutant...
...inhibitor of EZH2 increased apoptosis compared with normal EZH2 expression or vehicle, respectively. In a BAP1-knockout...
...and other disease markers compared with normal EZH2 expression. In a xenograft mouse model of BAP1-mutant...
BioCentury | Dec 8, 2011
Targets & Mechanisms

Proteasome DUBstep

Karolinska Institute researchers have identified a small molecule proteasome inhibitor for cancer that has a distinct mechanism from other compounds in the class. 1 Vivolux AB has licensed the candidate, which blocks two proteasome-associated deubiquitinating...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Proteasome In vitro and mouse studies identified a small molecule proteasome inhibitor that could help treat cancer. In vitro, the...
BioCentury | Oct 31, 2011
Company News

Castle Biosciences, Washington University deal

...worldwide rights from the university to IP related to the BRCA1-associated protein 1 (BAP1) gene. Castle will incorporate BAP1...
BioCentury | Nov 18, 2010
Distillery Therapeutics

Indication: Cancer

...Cancer Melanoma BRCA1-associated protein 1 (BAP1) Studies in patient tissue samples and in cell culture suggest that mutant BAP1...
...somatic mutations in BAP1. In a uveal melanoma cell line, small interfering RNA knockdown of BAP1...
...include analyzing additional tumors and normal patient blood samples to further characterize the spectrum of BAP1...
Items per page:
1 - 10 of 17